Acadia Pharmaceuticals
ACAD
245 hedge funds and large institutions have $3.61B invested in Acadia Pharmaceuticals in 2021 Q2 according to their latest regulatory filings, with 41 funds opening new positions, 86 increasing their positions, 72 reducing their positions, and 68 closing their positions.
190% more call options, than puts
Call options by funds: $47.5M | Put options by funds: $16.4M
19% more repeat investments, than reductions
Existing positions increased: 86 | Existing positions reduced: 72
1.6% more ownership
Funds ownership: 90.84% → 92.44% (+1.6%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
4% less capital invested
Capital invested by funds: $3.76B → $3.61B (-$147M)
10% less funds holding
Funds holding: 272 → 245 (-27)
40% less first-time investments, than exits
New positions opened: 41 | Existing positions closed: 68
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$61.8M |
| 2 |
D.E. Shaw & Co
New York
|
+$54.4M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$41.6M |
| 4 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$34M |
| 5 |
First Trust Advisors
Wheaton,
Illinois
|
+$30.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
|
-$77.8M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$38.1M |
| 3 |
PA
Perceptive Advisors
New York
|
-$36.4M |
| 4 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$25.8M |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
-$25.6M |
ACAD Hedge Fund Activity: Q2 2021 in Review
245 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in Acadia Pharmaceuticals (ACAD) for Q2 2021, worth a combined $3.61B — down 3.9% from $3.76B a quarter earlier.
Sellers outnumbered buyers: 68 funds closed out of ACAD and 41 opened new positions — a net loss of 27 holders — while 72 trimmed existing stakes and 86 added.
The largest buyer was BlackRock, adding an estimated $61.8M. The largest seller was Janus Henderson Group, cutting an estimated $77.8M.
- 245 institutional investors held Acadia Pharmaceuticals (ACAD) as of Q2 2021, down from 272 in Q1 2021.
- Funds reported $3.61B of Acadia Pharmaceuticals stock for Q2 2021, down 3.9% quarter-over-quarter.
- 41 funds opened new Acadia Pharmaceuticals positions in Q2 2021 and 68 closed out, a net change of -27 holders.
- The largest Acadia Pharmaceuticals buyer in Q2 2021 was BlackRock, an estimated $61.8M added.
- The largest Acadia Pharmaceuticals seller in Q2 2021 was Janus Henderson Group, an estimated $77.8M sold.
Based on aggregated 13F filings for Q2 2021.